We are developing the first booster mRNA vaccine against variants of concern of the SARS-CoV-2 coronavirus. Our vaccine is designed to protect against the variant delta prevalent worldwide and the emerging variant omicron, both responsible for increased transmissibility of COVID-19 and limited efficacy of current vaccines.
Phylex Biosciences
is a next-generation vaccine company uniquely located at
the crossroads of information technology and biotechnology.
the crossroads of information technology and biotechnology.